Clinical trial
Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
NCT00393861 · Indiana University, Other · Completed
Key facts
| NCT number | NCT00393861 |
|---|---|
| Title | Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients |
| Official title | Phase II Study of Oxaliplatin Plus Bevacizumab Salvage Chemotherapy in Patients With Germ Cell Tumors |
| Lead sponsor | Indiana University, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Germ Cell and Embryonal |
| Intervention type | Drug |
| Interventions | Bevacizumab and Oxaliplatin |
| Enrollment | 29 |
| Start date | Oct 1, 2006 |
| Primary completion | Oct 1, 2012 |
| Completion | Nov 1, 2014 |
| First posted | Oct 30, 2006 |
| Last update posted | Mar 24, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: